Nkarta, Inc. (NASDAQ:NKTX) Receives Average Rating of "Moderate Buy" from Analysts
Nkarta, Inc. (NASDAQ:NKTX) has an average "Moderate Buy" rating from six analysts, with an average 12-month price target of $13.25 significantly above its current trading price of $1.97. The company is a clinical-stage biotechnology firm focused on off-the-shelf natural killer cell therapies for cancer. Recent insider selling by the CEO and institutional trading activity are noted, with institutions owning a significant portion of the stock.
Nkarta Insiders Make Handsome Sum Selling Stock At US$2.06 Per Share
Nkarta, Inc. (NASDAQ:NKTX) recently saw significant insider selling, with a large transaction by Paul Hastings at US$2.06 per share, below the current stock price of US$2.40. Over the past year, insiders have not purchased any shares, and recent selling activity totaled US$66k. This behavior, alongside minimal insider ownership (approximately US$770k), suggests caution for potential investors, despite the stock's recent 22% increase.
Nkarta (NKTX) president Nadir sells $11,693 in shares
Nkarta (NKTX) President Nadir Mahmood sold 5,649 shares of common stock for $11,693 to cover tax obligations related to Restricted Stock Units vesting. Following this, Mahmood directly owns 167,727 shares. The company is also advancing clinical programs for its NK cell therapy, NKX019, with Stifel adjusting its price target to $11 while maintaining a Buy rating.
Nkarta CEO Hastings sells $53,915 in NKTX stock By Investing.com
Nkarta CEO Paul J. Hastings sold 26,046 shares of NKTX stock worth $53,915 to cover tax obligations related to Restricted Stock Units vesting. Despite the sale, Hastings still directly owns 390,023 shares, and analysts maintain a bullish outlook on the company. Nkarta, a clinical-stage biotech company, recently announced positive clinical data for its NKX019 therapy and had its price target adjusted by Stifel from $12 to $11, while retaining a Buy rating due to accelerated trial enrollment.
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Moderate Buy" by Analysts
Nkarta, Inc. (NASDAQ:NKTX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $13.25. Insider selling by CEO Paul J. Hastings was reported, but institutional investors have shown mixed activity. The company is a clinical-stage biotech focusing on NK cell therapies for cancer.
Insider Selling: Nkarta (NASDAQ:NKTX) President Sells 5,649 Shares of Stock
Nkarta (NASDAQ:NKTX) President Nadir Mahmood recently sold 5,649 shares of the company's stock for $2.07 per share, reducing his total stake by 3.26%. The sale, totaling $11,693.43, leaves him with 167,727 shares valued at approximately $347,194.89. Despite this insider selling, Nkarta maintains a "Moderate Buy" consensus rating from analysts with an average price target of $13.25.
Insider Selling: Nkarta (NASDAQ:NKTX) CEO Sells 26,046 Shares of Stock
Nkarta (NASDAQ:NKTX) CEO Paul Hastings sold 26,046 shares of the company's stock on January 15th at an average price of $2.07, totaling $53,915.22. This sale reduced his stake by 6.26%, leaving him with 390,023 shares valued at approximately $807,347.61. The biopharmaceutical company's shares are trading around $2.04, and analysts maintain a "Moderate Buy" rating with an average target price of $13.25.
Nkarta CEO Hastings sells $53,915 in NKTX stock
Nkarta, Inc. CEO Paul J. Hastings sold 26,046 shares of common stock valued at $53,915 on January 15, 2026, to cover tax withholding obligations. The company, trading at $2.04 per share, holds more cash than debt, though it is burning through reserves. Analysts maintain a bullish outlook despite the recent transaction, with Stifel adjusting its price target to $11.00 while keeping a Buy rating.
Nkarta (NKTX) president Nadir sells $11,693 in shares
Nkarta, Inc.'s President, Nadir Mahmood, sold 5,649 shares of common stock for $11,693 to cover tax obligations. This sale occurred on January 15, 2026, and Mahmood now directly owns 167,727 shares. The company is also set to present new clinical data for its NK cell therapy, NKX019, and Stifel adjusted its price target for Nkarta, maintaining a Buy rating.
Nkarta CEO Hastings sells $53,915 in NKTX stock
Nkarta CEO Paul J. Hastings sold 26,046 shares of NKTX common stock for $53,915 on January 15, 2026, to cover tax obligations. The clinical-stage biotech company, currently trading at $2.04, is considered undervalued by InvestingPro despite having strong liquidity and a 10.27% year-to-date return. Nkarta also recently announced positive clinical data for its NKX019 therapy and received an adjusted price target of $11.00 from Stifel, which maintained a Buy rating.
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts
Nkarta, Inc. (NASDAQ:NKTX) has received an average rating of "Moderate Buy" from analysts, with six firms covering the stock, resulting in an average 1-year target price of $13.25. The company currently has a market capitalization of $130.7 million, and institutional investors hold approximately 80.54% of its shares. Recent institutional activity shows various funds increasing their positions in Nkarta, reflecting a notable level of investor interest.
Nkarta (NASDAQ:NKTX) Rating Increased to Hold at Wall Street Zen
Wall Street Zen upgraded Nkarta (NASDAQ:NKTX) from a "sell" to a "hold" rating, contributing to a "Moderate Buy" consensus and an average target price of $13.25 among analysts. Despite mixed analyst coverage, Nkarta showed strong institutional ownership and beat Q3 EPS estimates. The company, a clinical-stage biotechnology firm specializing in NK cell therapies for cancer, has a market cap of $127.14 million.
Nkarta Shares Show Signs of Finding a Floor
Nkarta Inc.'s stock saw a 1.70% gain with significantly increased trading volume, suggesting renewed investor interest after a period of selling pressure. The company's NK cell therapy program is progressing, with a new lymphodepletion regimen achieving complete B-cell depletion in patients. Despite a mixed technical outlook, Nkarta's strong financial position and "Moderate Buy" analyst consensus indicate potential upside.
Nkarta (NASDAQ:NKTX) Downgraded by Wall Street Zen to Sell
Wall Street Zen downgraded Nkarta (NASDAQ:NKTX) from a "hold" to a "sell" rating. Despite this PESSIMISTIC action, the consensus among analysts remains a "Moderate Buy" with a $13.25 price target. Nkarta reported Q3 EPS of -$0.29, beating estimates by $0.03, and institutional investors hold a significant portion of its shares.
NKTX: Robust I&I data expected next year, with accelerated enrollment and strong financial runway
Nkarta, Inc. (NKTX) anticipates robust data from its I&I program next year, following a delay to ensure strong results from an updated Flu/Cy regimen. The trial has improved enrollment and engagement, now utilizing a basket design across five indications. NKTX also has strong FDA support and a cash runway extending into 2029.
Nkarta, Inc. (NASDAQ:NKTX) Receives Average Recommendation of "Moderate Buy" from Analysts
Nkarta, Inc. (NASDAQ:NKTX) has an average "Moderate Buy" recommendation from six analysts, with a consensus 12-month target price of $13.25. The clinical-stage biopharmaceutical company is developing natural killer cell therapies, and its lead candidate, NKX019, is in Phase 1 trials for non-Hodgkin lymphoma and lupus nephritis. Nkarta recently reported better-than-expected EPS and has significant institutional investor interest.
Nkarta to Participate in Evercore Healthcare Conference
Nkarta, Inc. announced its participation in the Evercore 8th Annual Healthcare Conference on December 4, 2025, where it will host a fireside chat at 10:50 a.m. ET. The clinical-stage biopharmaceutical company is developing engineered natural killer (NK) cell therapies for autoimmune diseases. A webcast of the event will be available on the Investors section of Nkarta’s website, with a replay archived for approximately 90 days.
Nkarta to Participate in Evercore Healthcare Conference
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for autoimmune diseases, announced its participation in the Evercore 8th Annual Healthcare Conference. The company will present on December 4, 2025, at 10:50 a.m. ET via a fireside chat, with a webcast available on their investors section. Nkarta is advancing allogeneic, off-the-shelf NK cell therapies utilizing its cell expansion and cryopreservation platform along with proprietary cell engineering.
Nkarta (NASDAQ: NKTX) posts $316.5M cash; second NKX019 dose-escalation cohort underway
Nkarta (NASDAQ: NKTX) reported its Q3 2025 financial results, announcing $316.5 million in cash and investments, projected to fund operations into 2029. The company also announced that the second dose-escalation cohort for its NKX019 autoimmune program is now underway, following clearance from a combined independent Data Safety Monitoring Board (iDSMB). Initial data for NKX019 in multiple autoimmune indications is expected to be presented at a medical conference in 2026.
Nkarta (Nasdaq: NKTX) to join fireside chats at Stifel, TD Cowen Nov. 12–13
Nkarta (NKTX) announced its participation in two investor conferences in November 2025. The clinical-stage biopharmaceutical company will engage in fireside chats at the Stifel 2025 Healthcare Conference on November 12 and the TD Cowen Immunology & Inflammation Summit on November 13. Webcasts of both events will be available on Nkarta's investor website, with replays archived for 90 days.
Nkarta (NASDAQ: NKTX) presenting ACR 2025 poster on NKX019, including B-cell depletion data
Nkarta (NASDAQ: NKTX) announced they will present clinical and preclinical data for their investigational therapy NKX019 at the American College of Rheumatology (ACR) Convergence 2025 meeting. The data will highlight robust B-cell depletion and reconstitution, consistent with immune reset in non-Hodgkin lymphoma patients, and illustrate NKX019's potential for B-cell driven autoimmune diseases. Mira Tohmé, PhD, will present the poster.
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
Nkarta, Inc. announced its third-quarter 2025 financial results, highlighting significant progress in its NKX019 clinical program for autoimmune diseases. The company has streamlined enrollment across its Ntrust-1 and Ntrust-2 clinical trials and has observed deep B-cell depletion in patients receiving NKX019 with a modified lymphodepletion regimen. Nkarta reported a cash balance of $316.5 million, which is expected to fund operations into 2029, and anticipates presenting initial data for NKX019 in multiple autoimmune indications in 2026.
Stifel lowers Nkarta stock price target to $11 from $12, keeps Buy rating
Stifel has lowered its price target for Nkarta Inc. (NASDAQ:NKTX) from $12 to $11 while retaining a Buy rating, citing the stock as significantly undervalued despite a 42% drop over the past year. The firm's decision to update its outlook follows Nkarta's move to accelerate patient enrollment in Ntrust-1/2 trials and to present a comprehensive data set at a medical conference in 2026, rather than a more limited disclosure in late 2025. This change, coupled with a reinstated fludarabine utilization in lymphodepletion protocols, is expected to improve enrollment efficiency and data quality for the company's NK cell therapy.
Nkarta to Participate in November Investor Conferences
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company, announced its participation in two investor conferences in November: the Stifel 2025 Healthcare Conference and TD Cowen’s Immunology & Inflammation Summit. The company will host fireside chats at both events, with webcasts available on its investor relations website for those unable to attend in person. Nkarta is focused on developing allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases.
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
Nkarta, Inc. will present clinical data at the American College of Rheumatology (ACR) Convergence 2025 meeting on its investigational therapy, NKX019. The presentation will highlight NKX019's ability to deplete pathogenic B-cells in non-Hodgkin lymphoma patients and its potential for treating B-cell driven autoimmune diseases. This engineered allogeneic NK cell therapy aims to selectively deplete disease-driving B cells without inducing significant toxicities.
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
Nkarta, Inc. will present clinical and preclinical data on its investigational therapy, NKX019, at the American College of Rheumatology (ACR) Convergence 2025 meeting. The data demonstrate NKX019's potential to deplete pathogenic B-cells and induce immune reset in non-Hodgkin lymphoma and autoimmune disease models. This highlights NKX019 as a novel therapeutic approach for B-cell driven autoimmune diseases.
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Moderate Buy" by Analysts
Nkarta, Inc. (NASDAQ:NKTX) has received a consensus "Moderate Buy" recommendation from analysts, with an average target price of $13.50. Despite this positive sentiment, the stock recently dropped 8.5% to $2.16, significantly below its 52-week high. Institutional investors have actively traded Nkarta shares, while the company reported better-than-expected earnings for the last quarter.
Clinical-Stage NK Cell Therapy Pioneer Nkarta to Share Updates at Major Healthcare Conference
Nkarta (NASDAQ: NKTX), a clinical-stage biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company will host a fireside chat on September 9, 2025, at 8:30 a.m. ET, with a live webcast and replay available on its website. This presentation is part of Nkarta's ongoing engagement with investors to discuss its advancements in allogeneic, off-the-shelf NK cell therapies for autoimmune diseases.
Nkarta, Inc. Appoints Dr. Shawn Rose as Chief Medical Officer and Head of R&D
Nkarta, Inc. has announced the appointment of Dr. Shawn Rose as its new Chief Medical Officer and Head of R&D, effective June 23, 2025, succeeding Dr. David R. Shook. Dr. Rose brings extensive experience in immunology translational medicine, having contributed to multiple approved treatments. The company aims to leverage his expertise to advance its NK cell therapy initiatives for autoimmune diseases, including the development of NKX019.
Nkarta lays off 3rd of staff, including CFO, to fund autoimmune CAR NK program
Nkarta is laying off a third of its staff, including its CFO and other executives, to extend its cash runway into 2029 and fund its lead CAR NK candidate, NKX019, for autoimmune diseases. This move follows the company's strategic pivot from oncology to autoimmune disease, with trials for NKX019 in lupus nephritis, systemic sclerosis, and other conditions expected to show initial results in the second half of this year. While described as "unfortunate," analysts view the layoffs as a "necessary" step to advance the company's autoimmune CAR-NK cell approach.
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
The Law Offices of Frank R. Cruz announced an investigation into Nkarta, Inc. (NKTX) following a significant drop in its stock price. This investigation concerns possible violations of federal securities laws after Nkarta "deprioritized" its acute myeloid leukemia program, NKX101, due to a lower-than-expected response rate. The firm is inviting investors who suffered losses to participate in the investigation.
Nkarta Launches Trial for CAR-NK Therapy NKX019 in Lupus and Gains Clearance for Separate Trial in Other Autoimmune Diseases
Nkarta has initiated a clinical trial (Ntrust-1) for its investigational CAR-NK cell therapy, NKX019, in lupus nephritis, with the first patient now in screening. Concurrently, the company received FDA clearance for a separate trial (Ntrust-2) to evaluate NKX019 in systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis. These trials mark critical milestones for Nkarta as they aim to develop accessible and tolerable cell therapies for underserved autoimmune disease patients.
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
The global oncology cancer drugs market is projected to reach $289.2 billion by 2030, growing at an 8.4% CAGR, driven by an aging population and increasing cancer prevalence. Several biotech companies, including Oncolytics Biotech, Amgen, Ambrx Biopharma, Elevation Oncology, and Nkarta, are making significant advancements in cancer treatment and corporate development. Key announcements include Oncolytics Biotech's board appointment, Amgen's LUMAKRAS FDA review, Johnson & Johnson's acquisition of Ambrx, and clinical trial updates from Elevation Oncology and Nkarta.
Nkarta to Present Preclinical Data from Engineered NK Cell Platform at the American Association for Cancer Research 2022 Annual Meeting
Nkarta, Inc. announced plans to present four posters at the American Association for Cancer Research (AACR) 2022 Annual Meeting. These presentations will include preclinical data from their engineered natural killer (NK) cell platform, with one presentation jointly made with CRISPR Therapeutics. The abstracts are already available, and posters will be made electronically accessible on April 8, 2022.
Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML
Nkarta, Inc. announced that the U.S. FDA has granted Orphan Drug Designation (ODD) to NKX101 for the treatment of acute myeloid leukemia (AML). NKX101 is an investigational NK cell therapy currently in a Phase 1 clinical trial for adults with relapsed/refractory AML or myelodysplastic syndrome (MDS). This designation acknowledges the urgent need for new treatment options for AML patients and provides potential development incentives for Nkarta.
Gates Biomanufacturing Facility Announces Strategic Manufacturing Agreement with Cell Therapy Pioneer, Nkarta
The Gates Biomanufacturing Facility (GBF) announced a continued strategic manufacturing agreement with Nkarta, Inc. for the production of NKX101, Nkarta's investigational NK cell therapy. This collaboration involves GBF manufacturing the clinical supply of therapeutic Natural Killer cells at its facility on the University of Colorado Anschutz Medical Campus. The partnership highlights GBF's role in advancing innovative cell therapies for conditions like relapsed/refractory acute myeloid leukemia.
Paul Hastings' journey from patient to one of biotech's leading voices - San Francisco Business Times
The article profiles Paul Hastings, CEO of Nkarta Therapeutics, highlighting his unique journey as a patient, biotech CEO, and gay Democrat. It emphasizes his role as one of biotech's leading voices and his familiarity with Capitol Hill during a critical period for the drug-development industry.
